The U.S. influenza diagnostics market size is expected to reach USD 166.0 million by the year 2026 growing at a CAGR of 5.4% according to a new report by Grand View Research, Inc. Key drivers of the market include rising disease prevalence, increase in geriatric population and high-risk population for influenza such as children, pregnant women and immunosuppressed patients suffering from various chronic diseases. The rise in the prevalence of the flu in the U.S. is expected to boost market growth. Data from CDC indicates that flu incidence was relatively low in the months of October 2018 and November 2018, however, rise in the number of cases was witnessed in December 2018 and remained high until February 2019. Influenza A was dominant in the southeastern part of the U.S. During 2018-2019 flu season, 536,301 specimens were tested in laboratories out of which 54,381 tested positive, among which 52,028 were of influenza A and 2,353 of influenza B. These facts are indicative of the rising prevalence of the flu, necessitating increasing demand for diagnostic products. Additionally, individuals with a high risk of contracting the influenza virus consist of children, pregnant women, immunosuppressed patients suffering from chronic diseases and healthcare workers. For instance, 28 pediatric deaths have been reported by the CDC in 2018-2019 indicative of the rising disease incidence. According to the CDC in 2018-2019, 1654 individuals aged 65 years of age and above were diagnosed with flu. Owing to their immunosuppressed state, this population group is more susceptible to flu and other infectious diseases causing complications. Thus, timely diagnosis facilitated by home care testing kits is further anticipated to fuel the market growth during the forecast period. RDITs held the largest market share in 2018 as they are easily available and are user-friendly facilitating rapid diagnosis. In addition, key participants are engaged in various inorganic and organic strategic developments to expand their existing product portfolios and geographic expansion. For instance, in 2018, Quidel Corporation received 510(k) FDA clearance for their CLIA waived QuickVue Influenza A+B assay to be used for the rapid diagnosis of influenza A & B. This assay facilitates rapid detection of influenza B & A antigens by nasopharyngeal and nasal swab from patients. Hospitals held the largest market share in 2018 due to the rise in prevalence of flu. POCT is one of the fastest-growing segments due to technologically advanced products offered by leading players. For instance, in 2016, Becton, Dickinson, and Company launched a new wireless BD Veritor Plus System which is a rapid diagnostic device for the detection of B & A virus subtypes. This product serves hospitals, clinics, and laboratories. BD Veritor Plus System consists of BD cloud connectivity solution that allows users to transfer data securely to an electronic medical record. These factors are thus anticipated to positively impact market potential during the forecast period. Further key findings from the report suggest: • Commercial availability of RIDTs and quick turnaround times are major factors that attribute to its large market share. • The hospitals market for U.S. influenza diagnostics held the largest market share in 2018 but is expected to gradually slow down with the advent of POCT. • Some major players catering to the U.S. influenza diagnostics market are Alere, 3M Health Care, Meridian Bioscience, Inc., Becton, Dickinson and Company, Quidel Corporation, Meridian Bioscience, Inc., SA Scientific, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc. and Sekisui Diagnostics.
Table of Contents Chapter 1 Methodology and Scope 1.1 Research Methodology 1.1.1 Information Procurement 1.2 Information Or Data Analysis 1.3 Market Formulation & Validation 1.4 Region-Wise Market Calculation 1.4.1 Region-Wise Market: Base Estimates 1.4.2 U.S. Market: Cagr Calculation 1.5 Region-Based Segment Share Calculation 1.6 List Of Secondary Sources 1.7 List Of Primary Sources 1.7.1 Primary Interview Breakup 126.96.36.199 Data For Primary Interviews, By Sources 188.8.131.52 Data For Primary Interviews, By Region Chapter 2 Executive Summary 2.1 Market Snapshot Chapter 3 U.S. Influenza Diagnostics Market Variables, Trends & Scope 3.1 Market Segmentation & Scope 3.1.1 Market Driver Analysis 184.108.40.206 Rising Geriatric Population 220.127.116.11 Increasing Prevalence Of Chronic Diseases 18.104.22.168 Government Initiatives To Counter Influenza 22.214.171.124 Technological Advancements 3.1.2 Market Restraint Analysis 126.96.36.199 Product Safety And High Development Costs 3.1.3 Key Opportunities Prioritized 188.8.131.52 Key Opportunities Prioritized, By Test Type 184.108.40.206 Key Opportunities Prioritized, By End Use 3.1.4 U.S. Influenza Diagnostics - Swot Analysis, By Factor (Political & Legal, Economic And Technological) 3.1.5 Industry Analysis - Porter's 3.1.6 U.S. Influenza Diagnostics Market: Company Market Position Analysis, 2018 Chapter 4 U.S. Influenza Diagnostics Market: Test Type Analysis 4.1 Test Type Business Analysis 4.2 U.S. Influenza Diagnostics Market: Test Type Movement Analysis 4.2.1 Ridts 220.127.116.11 Ridts Market Estimates And Forecasts, 2015 - 2026 (USD Million) 4.2.2 Rt-Pcr 18.104.22.168 Rt-Pcr Market Estimates And Forecasts, 2015 - 2026 (USD Million) 4.2.3 Cell Culture 22.214.171.124 Cell Culture Market Estimates And Forecasts, 2015 - 2026 (USD Million) 4.2.4 Other Diagnostic Tests 126.96.36.199 Other Diagnostic Tests Market Estimates And Forecasts, 2015 - 2026 (USD Million) Chapter 5 U.S. Influenza Diagnostics Market: End Use Analysis 5.1 End Use Business Analysis 5.2 U.S. Influenza Diagnostics Market: End Use Movement Analysis 5.2.1 Hospitals 188.8.131.52 Hospitals Market Estimates And Forecasts, 2015 - 2026 (USD Million) 5.2.2 Poct 184.108.40.206 Poct Market Estimates And Forecasts, 2015 - 2026 (USD Million) 5.2.3 Laboratories 220.127.116.11 Laboratories Market Estimates And Forecasts, 2015 - 2026 (USD Million) Chapter 6 U.S. Influenza Diagnostics Market: Regional Estimates & Trend Analysis, By Test Type, End Use 6.1 U.S. Chapter 7 Competitive Landscape 7.1 Company Profiles 7.1.1 3M COMPANY 18.104.22.168 Company Overview 22.214.171.124 Financial Performance 126.96.36.199 Product Benchmarking 7.1.2 ALERE 188.8.131.52 Company Overview 184.108.40.206 Product Benchmarking 220.127.116.11 Strategic Initiatives 7.1.3 BECTON, DICKINSON AND COMPANY (BD) 18.104.22.168 Company Overview 22.214.171.124 Financial Performance 126.96.36.199 Product Benchmarking 188.8.131.52 Strategic Initiatives 7.1.4 MERIDIAN BIOSCIENCE, INC. 184.108.40.206 Company Overview 220.127.116.11 Financial Performance 18.104.22.168 Product Benchmarking 7.1.5 QUIDEL CORPORATION 22.214.171.124 Company Overview 126.96.36.199 Financial Performance 188.8.131.52 Product Benchmarking 7.1.6 ROCHE DIAGNOSTICS CORPORATION 184.108.40.206 Company Overview 220.127.116.11 Financial Performance 18.104.22.168 Product Benchmarking 22.214.171.124 Strategic Initiatives 7.1.7 SA SCIENTIFIC 126.96.36.199 Company Overview 188.8.131.52 Financial Performance 184.108.40.206 Product Benchmarking 7.1.8 SEKISUI DIAGNOSTICS 220.127.116.11 Company Overview 18.104.22.168 Financial Performance 22.214.171.124 Product Benchmarking 126.96.36.199 Strategic Initiatives 7.1.9 THERMO FISHER SCIENTIFIC, INC. 188.8.131.52 Company Overview 184.108.40.206 Financial Performance 220.127.116.11 Product Benchmarking 18.104.22.168 Strategic Initiatives
List of Tables Table 1 List of key distributors and channel partners Table 2 List of key emerging companies'/product disruptors/innovators Table 3 U.S influenza diagnostics Market, by test type, 2015 - 2026 (USD Million) Table 4 U.S influenza diagnostics Market, by end use, 2015 - 2026 (USD Million) Table 5 Influenza Diagnostic Tests Performed in the U.S. 2015 - 2026 (Thousands)
List of Figures Fig. 1 Market research process Fig. 2 Information procurement Fig. 3 Primary research pattern Fig. 4 Market research approaches Fig. 5 Value-chain-based sizing & forecasting Fig. 6 QFD modeling for market share assessment Fig. 7 Market formulation & validation Fig. 8 Primary interviews, by sources Fig. 9 Primary interviews, by region Fig. 10 U.S. influenza diagnostics market summary Fig. 11 U.S. Influenza diagnostics market trends and outlook Fig. 12 U.S. Influenza diagnostics market segmentation Fig. 13 U.S. influenza diagnostics market driver impact Fig. 14 U.S. influenza diagnostics market restraint impact Fig. 15 Key opportunities prioritized, test type Fig. 16 Key opportunities prioritized, end use Fig. 17 SWOT analysis, by factor (political & legal, economic and technological) Fig. 18 Porter's five forces analysis Fig. 19 U.S. influenza diagnostics market, Heat map analysis, 2018 Fig. 20 U.S. influenza diagnostics test type outlook: Key takeaways Fig. 21 U.S. influenza diagnostics market: Test type movement analysis Fig. 22 U.S. influenza RIDTs market, 2015 - 2026 (USD Million) Fig. 23 U.S. influenza RT-PCR market, 2015 - 2026 (USD Million) Fig. 24 U.S. influenza cell culture market, 2015 - 2026 (USD Million) Fig. 25 U.S. influenza other diagnostic tests market, 2015 - 2026 (USD Million) Fig. 26 U.S. Influenza Diagnostics market end use outlook: Key takeaways Fig. 27 U.S. Influenza Diagnostics market: End use movement analysis Fig. 28 U.S. influenza hospitals market, 2015 - 2026 (USD Million) Fig. 29 U.S. influenza POCT market, 2015 - 2026 (USD Million) Fig. 30 U.S. influenza laboratories market, 2015 - 2026 (USD Million)
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.